LILRA5 and COVID-19: To the best of our knowledge, this is the first time that LILRA5 has been identified as being upregulated in the serum of patients with COVID-19 as a novel potential biomarker, which was only previously found to be upregulated in the kidneys of patients with COVID-19 at the mRNA level [68].